Study of IBI311 for people with inactive thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your thyroid eye disease has been stable (no worsening) for at least 6 months
- The bulging in at least one eye is 20 mm or more
- You were first diagnosed with thyroid eye disease at least 2 years ago, but less than 10 years ago
- You have not used steroids or other immune-suppressing treatments recently
- You are not pregnant and agree to use birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called IBI3031 to treat active thyroid eye disease (TED), a condition where the immune system attacks muscles and tissue around the eyes, causing swelling, bulging, and sometimes double vision. The study aims to see if this drug can reduce inflammation and improve symptoms.
This study tests a new medication (NTB003) for people with thyroid eye disease (TED), a condition that can cause bulging eyes, double vision, and discomfort. It aims to see if the treatment is safe and helps reduce symptoms.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
This study tests an investigational drug, KHN939, for people with moderate-to-severe inactive thyroid eye disease (also called Graves' eye disease). The goal is to see if the drug can improve symptoms such as bulging eyes and double vision. Participation lasts for several months and involves regular check-ups.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This trial tests two doses of an oral medication (linsitinib) for people with active, moderate-to-severe thyroid eye disease who were in a previous study and didn't improve enough or had their bulging come back. It aims to see if continuing treatment can help with eye bulging and other symptoms.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.